Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial Full Text
Boston Scientific, 09/30/2011
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patients in its NECTAR–HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. NECTAR–HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients. The study will evaluate 96 patients with vagal nerve stimulator implants at multiple centers in Europe.